The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439 · see citing works

Macrophage Diversity Enhances Tumor Progression and Metastasis

Qian, B., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,208 · see citing works

The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited

Fidler, I. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1098 · Cited by 4,686 · see citing works

Alternative activation of macrophages: mechanism and functions

Gordon, S., & Martinez, F. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.007 · Cited by 4,197 · see citing works

Tumor-Associated Macrophages: From Mechanisms to Therapy

Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · see citing works

Clonal heterogeneity and tumor evolution: past, present, and the future

McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840 · see citing works

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290 · see citing works

Distinct role of macrophages in different tumor microenvironments

Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225 · see citing works

Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide

Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101 · see citing works

Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems

Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878 · see citing works

Translational biology of osteosarcoma

Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294 · see citing works

TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor.

Wong, B. R., Josien, R., Lee, S. Y., Sauter, B., Li, H.-L., Steinman, R. M., & Choi, Y. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.12.2075 · Cited by 853 · see citing works

Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models

Siolas, D., & Hannon, G. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1069 · Cited by 672 · see citing works

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling

Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663 · see citing works

Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond

Walsh, M. C., & Choi, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00511 · Cited by 599 · see citing works

Mesenchymal Stem Cell-Derived Extracellular Vesicles as Mediators of Anti-Inflammatory Effects: Endorsement of Macrophage Polarization

Sicco, C. L., Reverberi, D., Balbi, C., Ulivi, V., Principi, E., Pascucci, L., Becherini, P., Bosco, M. C., Varesio, L., Franzin, C., et al. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.16-0363 · Cited by 560 · see citing works

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 537 · see citing works

Cancer stem cell niche: the place to be

Borovski, T., De Sousa E Melo, F., Vermeulen, L., & Medema, J. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3220 · Cited by 518 · see citing works

Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents

Buddingh, E. P., Kuijjer, M. L., Duim, R. A. J., Bürger, H., Agelopoulos, K., Myklebost, O., Serra, M., Mertens, F., Hogendoorn, P. C. W., Lankester, A. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2047 · Cited by 508 · see citing works

Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M Signaling

Guihard, P. J., Danger, Y., Royer, B. B.-L., David, E., Brion, R., Delécrin, J., Richards, C. D., Chevalier, S., Rédiní, F., Heymann, D., et al. (2012) · Stem Cells · doi:10.1002/stem.1040 · Cited by 477 · see citing works

Exploiting the curative potential of adoptive T‐cell therapy for cancer

Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466 · see citing works

Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts

Hoffman, R. M. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3972 · Cited by 424 · see citing works

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

Kovac, M., Blattmann, C., Ribi, S., Smida, J., Mueller, N. S., Engert, F., Castro-Giner, F., Weischenfeldt, J., Kovacova, M., Krieg, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9940 · Cited by 353 · see citing works

The B7 Family and Cancer Therapy: Costimulation and Coinhibition

Zang, X., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1030 · Cited by 335 · see citing works

Mechanisms of bone repair and regeneration

Deschaseaux, F., Sensebé, L., & Heymann, D. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.07.002 · Cited by 322 · see citing works

The biology of normal bone remodelling

Katsimbri, P. (2017) · European Journal of Cancer Care · doi:10.1111/ecc.12740 · Cited by 308 · see citing works

Cancer stem cells in osteosarcoma

Brown, H. K., Tellez-Gabriel, M., & Heymann, D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.11.019 · Cited by 303 · see citing works

Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

Grimaud, E., Soubigou, L., Couillaud, S., Coipeau, P., Moreau, A., Passuti, N., Gouin, F., Redini, F., & Heymann, D. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63560-2 · Cited by 282 · see citing works

Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma

Koirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267 · see citing works

Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?

Mutsaers, A. J., & Walkley, C. R. (2014) · Bone · doi:10.1016/j.bone.2014.02.003 · Cited by 233 · see citing works

Bone microenvironment signals in osteosarcoma development

Alfranca, A., Martínez-Cruzado, L., Tornín, J., Abarrategi, A., Amaral, A. T., de Álava, E., Menéndez, P. R., Garcı́a-Castro, J., & Rodrı́guez, R. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1918-y · Cited by 225 · see citing works

Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression

Ahmed, N., Salsman, V. S., Yvon, E., Louis, C. U., Perlaky, L., Wels, W. S., Dishop, M. K., Kleinerman, E. E., Pule, M., Rooney, C. M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.133 · Cited by 215 · see citing works

Osteoclastic acidification pathways during bone resorption

Rousselle, A. V., & Heymann, D. (2002) · Bone · doi:10.1016/s8756-3282(02)00672-5 · Cited by 210 · see citing works

Interleukin‐34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment

Ségaliny, A. I., Mohamadi, A., Dizier, B., Lokajczyk, A., Brion, R., Lanel, R., Amiaud, J., Charrier, C., Boisson‐Vidal, C., & Heymann, D. (2015) · International Journal of Cancer · doi:10.1002/ijc.29376 · Cited by 199 · see citing works

Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions

Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000065 · Cited by 197 · see citing works

Programmed Cell Death Ligand 1 Expression in Osteosarcoma

Shen, J. K., Cote, G. M., Choy, E., Yang, P., Harmon, D. C., Schwab, J. H., Nielsen, G. P., Chebib, I. A., Ferrone, S., Wang, X., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0224 · Cited by 195 · see citing works

Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment

Zachar, L., Bačenková, D., & Rosocha, J. (2016) · Journal of Inflammation Research · doi:10.2147/jir.s121994 · Cited by 191 · see citing works

Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression

Baglio, S. R., Lagerweij, T., Pérez-Lanzón, M., Ho, X. D., Léveillé, N., Melo, S. A., Cleton-Jansen, A.-M., Jordanova, E. S., Roncuzzi, L., Greco, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2726 · Cited by 187 · see citing works

B7-H3 is Overexpressed in Patients Suffering Osteosarcoma and Associated with Tumor Aggressiveness and Metastasis

Wang, L., Zhang, Q., Chen, W., Shan, B., Ding, Y., Zhang, G., Cao, N., Liu, L., & Zhang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070689 · Cited by 177 · see citing works

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma

Krishnadas, D. K., Shusterman, S., Bai, F., Diller, L., Sullivan, J. E., Cheerva, A. C., George, R. E., & Lucas, K. G. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1731-3 · Cited by 176 · see citing works

Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma

Dumars, C., Ngyuen, J.-M., Gaultier, A., Lanel, R., Corradini, N., Gouin, F., Heymann, D., & Heymann, M. (2016) · Oncotarget · doi:10.18632/oncotarget.13055 · Cited by 174 · see citing works

Macrophages and skeletal health

Michalski, M. N., & McCauley, L. K. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.017 · Cited by 172 · see citing works

RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases

Baud’huin, M., Lamoureux, F., Duplomb, L., Rédiní, F., & Heymann, D. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7104-0 · Cited by 171 · see citing works

Mesenchymal stroma: Role in osteosarcoma progression

Cortini, M., Avnet, S., & Baldini, N. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.024 · Cited by 171 · see citing works

All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated Macrophages

Zhou, Q., Xian, M., Xiang, S., Xiang, D., Shao, X., Wang, J., Cao, J., Yang, X., Yang, B., Ying, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0259 · Cited by 167 · see citing works

RANK–RANKL signalling in cancer

Renema, N., Navet, B., Heymann, M., Lézot, F., & Heymann, D. (2016) · Bioscience Reports · doi:10.1042/bsr20160150 · Cited by 164 · see citing works

Interleukin‐34 is expressed by giant cell tumours of bone and plays a key role in RANKL‐induced osteoclastogenesis

Baud’huin, M., Renault, R., Charrier, C., Riet, A., Moreau, A., Brion, R., Gouin, F., Duplomb, L., & Heymann, D. (2010) · The Journal of Pathology · doi:10.1002/path.2684 · Cited by 159 · see citing works

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model

Jespersen, H., Lindberg, M. F., Donia, M., Forsberg, E. M. V., Andersen, R. S., Keller, U. B., Ny, L., Svane, I. M., Nilsson, L. M., & Nilsson, J. A. (2017) · Nature Communications · doi:10.1038/s41467-017-00786-z · Cited by 159 · see citing works

Multimodal transfer of MDR by exosomes in human osteosarcoma

Torreggiani, E., Roncuzzi, L., Perut, F., Zini, N., & Baldini, N. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3509 · Cited by 155 · see citing works

CD163 + M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma

Han, Q., Shi, H., & Liu, F. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.01.023 · Cited by 149 · see citing works

Mifamurtide for the treatment of nonmetastatic osteosarcoma

Ando, K., Mori, K., Corradini, N., Rédiní, F., & Heymann, D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.543129 · Cited by 144 · see citing works

Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations

Bousquet, M., Noirot, C., Accadbled, F., de Gauzy, J. S., Castex, M., Brousset, P., & Gomez‐Brouchet, A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw009 · Cited by 143 · see citing works

CD8 + /FOXP3 + -ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study

Fritzsching, B., Fellenberg, J., Moskovszky, L. E., Sápi, Z., Krenács, T., Machado, I., Poeschl, J., Lehner, B., Szendrői, M., Bosch, A. L., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.990800 · Cited by 140 · see citing works

Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma

Maekawa, N., Konnai, S., Okagawa, T., Nishimori, A., Ikebuchi, R., Izumi, Y., Takagi, S., Kagawa, Y., Nakajima, C., Suzuki, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157176 · Cited by 140 · see citing works

Bisphosphonates: new therapeutic agents for the treatment of bone tumors

Heymann, D., Ory, B., Gouin, F., Green, J. R., & Rédiní, F. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.05.007 · Cited by 134 · see citing works

Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation

Avnet, S., Pompo, G. D., Chano, T., Errani, C., Ibrahim‐Hashim, A., Gillies, R. J., Donati, D. M., & Baldini, N. (2016) · International Journal of Cancer · doi:10.1002/ijc.30540 · Cited by 133 · see citing works

Tumor‐infiltrating lymphocytes for the treatment of metastatic cancer

Foppen, M. H. G., Donia, M., Svane, I. M., & Haanen, J. B. A. G. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.018 · Cited by 130 · see citing works

Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence

Perrot, P., Rousseau, J., Bouffaut, A.-L., Rédini, F., Cassagnau, E., Deschaseaux, F., Heymann, M.-F., Heymann, D., Duteille, F., Trichet, V., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010999 · Cited by 120 · see citing works

Concise Review: Mesenchymal Tumors: When Stem Cells Go Mad

Mohseny, A. B., & Hogendoorn, P. C. W. (2011) · Stem Cells · doi:10.1002/stem.596 · Cited by 118 · see citing works

Inflammatory Osteoclasts Prime TNFα-Producing CD4+ T Cells and Express CX3CR1

Ibáñez, L., Abou-Ezzi, G., Ciucci, T., Amiot, V., Belaïd, N., Obino, D., Mansour, A., Rouleau, M., Wakkach, A., & Blin-Wakkach, C. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2868 · Cited by 117 · see citing works

Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma

Rainusso, N., Brawley, V. S., Ghazi, A., Hicks, M. J., Gottschalk, S., Rosen, J. M., & Ahmed, N. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2011.83 · Cited by 114 · see citing works

Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy

Sundara, Y. T., Kostine, M., Cleven, A. H. G., Bovée, J. V. M. G., Schilham, M. W., & Cleton-Jansen, A.-M. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1925-3 · Cited by 111 · see citing works

Macrophage Delivery of an Oncolytic Virus Abolishes Tumor Regrowth and Metastasis after Chemotherapy or Irradiation

Muthana, M., Rodrigues, S., Chen, Y., Welford, A. F., Hughes, R., Tazzyman, S. J., Essand, M., Morrow, F. J., & Lewis, C. E. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-3056 · Cited by 104 · see citing works

The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis

Endo‐Munoz, L., Evdokiou, A., & Saunders, N. A. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.07.003 · Cited by 103 · see citing works

Antitumor and antimetastatic actions of dihydroxycoumarins (esculetin or fraxetin) through the inhibition of M2 macrophage differentiation in tumor-associated macrophages and/or G1 arrest in tumor cells

Kimura, Y., & Sumiyoshi, M. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.048 · Cited by 102 · see citing works

Decreased Ratio of CD8+ T Cells to Regulatory T Cells Associated with Decreased Survival in Dogs with Osteosarcoma

Biller, B. J., Guth, A., Burton, J. H., & DOW, S. W. (2010) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2010.0557.x · Cited by 100 · see citing works

Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B

Mori, K., Goff, B. L., Berreur, M., Riet, A. V., Moreau, A., Blanchard, F., Chevalier, C., Guisle, I., Leger, J. J., Guicheux, J., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2140 · Cited by 99 · see citing works

Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion

Cortini, M., Massa, A., Avnet, S., Bonuccelli, G., & Baldini, N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166500 · Cited by 97 · see citing works

γδ T Cells: Unexpected Regulators of Cancer Development and Progression

Fleming, C., Morrissey, S. M., Cai, Y., & Yan, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.06.003 · Cited by 97 · see citing works

Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells

Buddingh, E. P., Schilham, M. W., Ruslan, S. E. N., Berghuis, D., Szuhai, K., Suurmond, J., Taminiau, A. H. M., Gelderblom, H. A. J., Egeler, R. M., Serra, M., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0965-3 · Cited by 95 · see citing works

Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3

Tu, B., Zhu, J., Liu, S., Wang, L., Fan, Q., Hao, Y., Fan, C., & Tang, T.-T. (2016) · Oncotarget · doi:10.18632/oncotarget.10219 · Cited by 95 · see citing works

Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ

Pahl, J. H., Kwappenberg, K., Varypataki, E., Santos, S., Kuijjer, M., Mohamed, S., Wijnen, J., van Tol, M. V., Cleton-Jansen, A., Egeler, R., et al. (2014) · Journal of experimental & clinical cancer research : CR · doi:10.1186/1756-9966-33-27 · Cited by 94 · see citing works

Prognostic value of inflammation-based scores in patients with osteosarcoma

Liu, B., Huang, Y., Sun, Y., Zhang, J., Yao, Y., Shen, Z., Xiang, D., & He, A. (2016) · Scientific Reports · doi:10.1038/srep39862 · Cited by 89 · see citing works

RANKL blockade prevents and treats aggressive osteosarcomas

Chen, Y., Grappa, M. A. D., Molyneux, S. D., McKee, T. D., Waterhouse, P. D., Penninger, J. M., & Khokha, R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad0295 · Cited by 88 · see citing works

Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent

van Erp, A. E. M., Versleijen‐Jonkers, Y. M. H., Hillebrandt-Roeffen, M. H. S., van Houdt, L., Gorris, M. A. J., van Dam, L. S., Mentzel, T., Weidema, M. E., Savci-Heijink, C. D., Desar, I. M. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19071 · Cited by 88 · see citing works

Mesenchymal Stem/Stromal Cells under Stress Increase Osteosarcoma Migration and Apoptosis Resistance via Extracellular Vesicle Mediated Communication

Vallabhaneni, K. C., Hassler, M.-Y., Abraham, A., Whitt, J. D., Mo, Y., Atfi, A., & Pochampally, R. R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166027 · Cited by 87 · see citing works

Increased osteoclast activity is associated with aggressiveness of osteosarcoma

Avnet, S. (1992) · International Journal of Oncology · doi:10.3892/ijo_00000113 · Cited by 84 · see citing works

Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D–NKG2DL dependent manner

Fernández, L., Valentín, J., Zalacaín, M., Leung, W. H., Patiño‐García, A., & Pérez‐Martínez, A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.042 · Cited by 77 · see citing works

Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma

Théoleyre, S., Mori, K., Cherrier, B., Passuti, N., Gouin, F., Rédiní, F., & Heymann, D. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-123 · Cited by 75 · see citing works

Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours

Inagaki, Y., Hookway, E. S., Williams, K., Hassan, A. B., Oppermann, U. C. T., Tanaka, Y., Soilleux, E. J., & Athanasou, N. A. (2016) · Clinical Sarcoma Research · doi:10.1186/s13569-016-0053-3 · Cited by 68 · see citing works

Canonical and non-canonical pathways of osteoclast formation.

Knowles, H. J., & Athanasou, N. A. (2009) · PubMed · doi:10.14670/hh-24.337 · Cited by 67 · see citing works

Osteosarcoma: Current status of immunotherapy and future trends (Review)

Mori, K., Rédiní, F., Gouin, F., Cherrier, B., & Heymann, D. (2006) · Oncology Reports · doi:10.3892/or.15.3.693 · Cited by 66 · see citing works

Pre‐operative lymphocyte‐to‐monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma

Liu, T., Fang, X.-C., Ding, Z., Sun, Z.-G., Sun, L.-M., & Wang, Y.-L. (2015) · FEBS Open Bio · doi:10.1016/j.fob.2015.08.002 · Cited by 64 · see citing works

Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+ HLA-DRlo/neg) found in aggressive pediatric sarcoma patients

Hingorani, P., Maas, M. L., Gustafson, M. P., Dickman, P. S., Adams, R. H., Watanabe, M., Eshun, F., Williams, J., Seidel, M. J., & Dietz, A. B. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0082-0 · Cited by 62 · see citing works

Drugs in early clinical development for the treatment of osteosarcoma

Heymann, M., Brown, H. K., & Heymann, D. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1237503 · Cited by 62 · see citing works

Expression of programmed death 1 is correlated with progression of osteosarcoma

Zheng, W., Xiao, H. P., Liu, H., & Zhou, Y. (2014) · Apmis · doi:10.1111/apm.12311 · Cited by 60 · see citing works

IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway

Li, Z., Xu, Q., Peng, H., Cheng, R.-L., Sun, Z., & Ye, Z. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.001 · Cited by 59 · see citing works

Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug

Murakami, T., Igarashi, K., Kawaguchi, K., Kiyuna, T., Zhang, Y., Zhao, M. D., Hiroshima, Y., Nelson, S. D., Dry, S., Li, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14040 · Cited by 56 · see citing works

Adipose-derived mesenchymal stem cells promote osteosarcoma proliferation and metastasis by activating the STAT3 pathway

Wang, Y., Chu, Y., Yue, B., Ma, X., Zhang, G., Xiang, H., Liu, Y., Wang, T., Wu, X., & Chen, B. (2017) · Oncotarget · doi:10.18632/oncotarget.15866 · Cited by 56 · see citing works

Patterns of PD‐1, PD‐L1, and PD‐L2 expression in pediatric solid tumors

Pinto, N. R., Park, J. R., Murphy, E., Yearley, J. H., McClanahan, T., Annamalai, L., Hawkins, D. S., & Rudzinski, E. R. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26613 · Cited by 56 · see citing works

Tim3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients

Li, X., Chen, Y., Liu, X., Zhang, J. C., Xu, H., Teng, G., & Yu, D. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.01.006 · Cited by 54 · see citing works

Intra-arterial administration of tumor-targetingSalmonella typhimuriumA1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model

Igarashi, K., Kawaguchi, K., Murakami, T., Kiyuna, T., Miyake, K., Nelson, S. D., Dry, S., Li, Y., Yanagawa, J., Russell, T. A., et al. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1317417 · Cited by 54 · see citing works

A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology

Igarashi, K., Murakami, T., Kawaguchi, K., Kiyuna, T., Miyake, K., Zhang, Y., Nelson, S. D., Dry, S., Li, Y., Yanagawa, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19095 · Cited by 54 · see citing works

Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype

Rivoltini, L., Arienti, F., Orazi, A., Cefalo, G., Gasparini, M., Gambacorti-Passerini, C. B., Fossati‐Bellani, F., & Parmiani, G. (1992) · Cancer Immunology Immunotherapy · doi:10.1007/bf01741792 · Cited by 53 · see citing works

Establishment of a patient-derived orthotopic osteosarcoma mouse model

Blattmann, C., Thiemann, M., Stenzinger, A., Roth, E. K., Dittmar, A., Witt, H., Lehner, B., Renker, E. K., Jugold, M., Eichwald, V., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0497-x · Cited by 51 · see citing works

Anti-TGF-β Antibody Combined with Dendritic Cells Produce Antitumor Effects in Osteosarcoma

Kawano, M., Itonaga, I., Iwasaki, T., Tsuchiya, H., & Tsumura, H. (2012) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-012-2299-2 · Cited by 51 · see citing works

Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis

Zhu, Z., Jin, Z., Zhang, M., Tang, Y., Yang, G., Yuan, X., Yao, J., & Sun, D. (2017) · Oncotarget · doi:10.18632/oncotarget.19168 · Cited by 45 · see citing works

Killer Dendritic Cells Link Innate and Adaptive Immunity against Established Osteosarcoma in Rats

Chauvin, C., Philippeau, J.-M., Hémont, C., Hubert, F., Wittrant, Y., Lamoureux, F., Trinité, B., Heymann, D., Rédiní, F., & Josien, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0104 · Cited by 43 · see citing works

RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?

Cathomas, R. L., Rothermundt, C. A., Bode, B., Fuchs, B., von Moos, R., & Schwitter, M. (2014) · Oncology · doi:10.1159/000369975 · Cited by 42 · see citing works

Invariant NKT cells increase drug‐induced osteosarcoma cell death

Fallarini, S., Paoletti, T., Battaglini, N. O., & Lombardi, G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02108.x · Cited by 40 · see citing works

Aerosol interleukin‐2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis

Guma, S. R., Lee, D. A., Yu, L., Gordon, N. B., & Kleinerman, E. S. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25019 · Cited by 40 · see citing works

Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models

Rousseau, J., Escriou, V., Lamoureux, F., Brion, R., Chesneau, J., Battaglia, S., Amiaud, J., Scherman, D., Heymann, D., Rédiní, F., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.455 · Cited by 40 · see citing works

Sensitization of human osteosarcoma cells to Vγ9Vδ2 T‐cell‐mediated cytotoxicity by zoledronate

Li, Z., Peng, H., Xu, Q., & Ye, Z. (2011) · Journal of Orthopaedic Research® · doi:10.1002/jor.21579 · Cited by 40 · see citing works

Bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion

Yu, F., Hu, W., He, B., Zheng, Y., Zhang, Q., & Chen, L. (2015) · World Journal of Surgical Oncology · doi:10.1186/s12957-015-0465-1 · Cited by 38 · see citing works

Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma

KAWANO, M., TANAKA, K., ITONAGA, I., IWASAKI, T., MIYAZAKI, M., IKEDA, S., & TSUMURA, H. (2015) · Oncology Reports · doi:10.3892/or.2015.4161 · Cited by 38 · see citing works

Mast cells in atherosclerosis as a source of the cytokine RANKL

Ali, A. S., Lax, A.-S., Liljeström, M., Paakkari, I., Ashammakhi, N. A., Kovanen, P. T., & Konttinen, Y. T. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.117 · Cited by 37 · see citing works

Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases

Mori, K., Ando, K., & Heymann, D. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.2.151 · Cited by 37 · see citing works

Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells

Muraro, M., Mereuta, O. M., Carraro, F., Madon, E., & Fagioli, F. (2007) · Cellular Immunology · doi:10.1016/j.cellimm.2007.11.005 · Cited by 36 · see citing works

Potential of human γδ T cells for immunotherapy of osteosarcoma

Li, Z. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-2077-y · Cited by 33 · see citing works

Natural Killer Cells for Osteosarcoma

Tarek, N., & Lee, D. A. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_19 · Cited by 32 · see citing works

Patient-Derived Mouse Models of Cancer

Hoffman, R. M. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-57424-0 · Cited by 31 · see citing works

Improved Survival in Osteosarcoma Patients with Atypical Low Vascularization

Kunz, P., Fellenberg, J., Moskovszky, L. E., Sápi, Z., Krenács, T., Machado, I., Poeschl, J., Lehner, B., Szendrői, M., Ruef, P., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4001-2 · Cited by 29 · see citing works

Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics

Guilhamon, P., Butcher, L. M., Presneau, N., Wilson, G. A., Feber, A., Paul, D. S., Schütte, M., Haybaeck, J., Keilholz, U., Hoffman, J., et al. (2014) · Genome Medicine · doi:10.1186/s13073-014-0116-0 · Cited by 27 · see citing works

Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization

Benslimane-Ahmim, Z., Pereira, J. R. D. S., Lokajczyk, A., Dizier, B., Galy–Fauroux, I., Fischer, A., Heymann, D., & Boisson‐Vidal, C. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.032 · Cited by 25 · see citing works

Bone sarcomas: pathogenesis and new therapeutic approaches

Heymann, D., & Rédiní, F. (2011) · IBMS BoneKEy · doi:10.1138/20110531 · Cited by 23 · see citing works

In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma

He, Y.-T., Zhang, Q.-M., Kou, Q.-C., & Tang, B. (2016) · Oncology Letters · doi:10.3892/ol.2016.4714 · Cited by 22 · see citing works

Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice

Yin, S. J., Wang, W., & Zhang, J. Y. (2015) · Genetics and Molecular Research · doi:10.4238/2015.november.13.9 · Cited by 20 · see citing works

Genetically Modified T-Cell Therapy for Osteosarcoma

DeRenzo, C. C., & Gottschalk, S. M. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_18 · Cited by 18 · see citing works

Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells

Liu, M., Sun, L., Li, Y., Li, H., Zhang, J., Li, B., & Ye, Z. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.06.002 · Cited by 17 · see citing works

Effectiveness evaluation of dendritic cell immunotherapy for osteosarcoma on survival rate and in vitro immune response

Fang, X., Jiang, C., & Xia, Q. (2015) · Genetics and Molecular Research · doi:10.4238/2015.october.2.10 · Cited by 16 · see citing works

Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip

Tellez-Gabriel, M., Charrier, C., Brounais-Le Royer, B., Mullard, M., Brown, H. K., Verrecchia, F., & Heymann, D. (2017) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2017.01.003 · Cited by 14 · see citing works

Osteoblast-like cell line maintains in vitro rat peritoneal mast cell viability and functional activity.

Levi‐Schaffer, F., & Bar‐Shavit, Z. (1990) · PubMed · Cited by 12 · see citing works

Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect

Kiany, S., & Gordon, N. B. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3684-7_24 · Cited by 10 · see citing works

Proteoglycans and Osteolysis

Baud’huin, M., Charrier, C., Bougras-Cartron, G., Brion, R., Lézot, F., Padrines, M., & Heymann, D. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-498-8_21 · Cited by 7 · see citing works

Osteosarcoma

Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660 · see citing works

Molecular Biology of Osteosarcoma

Czarnecka, A. M., Synoradzki, K. J., Firlej, W., Bartnik, E., Sobczuk, P., Fiedorowicz, M., Grieb, P., & Rutkowski, P. L. (2020) · Cancers · doi:10.3390/cancers12082130 · Cited by 343 · see citing works

Identification and Verification of Immune-Related Gene Prognostic Signature Based on ssGSEA for Osteosarcoma

Xiao, B., Liu, L., Li, A., Xiang, C., Wang, P., Li, H., & Xiao, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.607622 · Cited by 330 · see citing works

Sarcoma treatment in the era of molecular medicine

Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319 · see citing works

Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies

Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 289 · see citing works

Osteosarcoma: A comprehensive review of management and treatment strategies

Jafari, F., Javdansirat, S., Sanaie, S., Naseri, A., Shamekh, A., Rostamzadeh, D., & Dolati, S. (2020) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2020.151654 · Cited by 253 · see citing works

Biology of Bone Sarcomas and New Therapeutic Developments

Brown, H. K., Schiavone, K., Gouin, F., Heymann, M.-F., & Heymann, D. (2018) · Calcified Tissue International · doi:10.1007/s00223-017-0372-2 · Cited by 163 · see citing works

Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma

Zhang, C., Zheng, J.-H., Lin, Z.-H., Lv, H.-Y., Ye, Z.-M., Chen, Y.-P., & Zhang, X.-Y. (2020) · Aging · doi:10.18632/aging.102824 · Cited by 160 · see citing works

Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment

Verrecchia, F., & Rédiní, F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00133 · Cited by 128 · see citing works

Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., et al. (2019) · Cancer · doi:10.1002/cncr.32351 · Cited by 127 · see citing works

Advances in Osteosarcoma

Panez-Toro, I., Muñoz-García, J., Vargas-Franco, J. W., Renodon‐Cornière, A., Heymann, M., Lézot, F., & Heymann, D. (2023) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00803-9 · Cited by 132 · see citing works

Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions

Wolf-Dennen, K., Gordon, N. B., & Kleinerman, E. S. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1747677 · Cited by 124 · see citing works

The role of tumor-associated macrophages in osteosarcoma progression – therapeutic implications

Huang, Q., Liang, X., Ren, T., Huang, Y., Zhang, H., Yu, Y., Chen, C., Wang, W., Niu, J., Lou, J., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00598-w · Cited by 118 · see citing works

Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications

Zhu, T., Han, J., Liu, Y., Cai, Z., Sun, W. Y., Hua, Y., & Xu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907550 · Cited by 113 · see citing works

A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA

Yang, M., Zheng, H., Xu, K., Yuan, Q., Aihaiti, Y., Cai, Y., & Xu, P. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.919231 · Cited by 112 · see citing works

Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity

Gabriel, M. T., Heymann, M., & Heymann, D. (2019) · Theranostics · doi:10.7150/thno.34337 · Cited by 111 · see citing works

Osteoimmunology of Oral and Maxillofacial Diseases: Translational Applications Based on Biological Mechanisms

Álvarez, C., Monasterio, G., Cavalla, F., Córdova, L. A., Hernández, M., Heymann, D., Garlet, G. P., Sorsa, T. A., Pärnänen, P., Lee, H., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01664 · Cited by 111 · see citing works

3D Cancer Models: The Need for a Complex Stroma, Compartmentalization and Stiffness

Pape, J., Emberton, M., & Cheema, U. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.660502 · Cited by 102 · see citing works

Complement C1q (C1qA, C1qB, and C1qC) May Be a Potential Prognostic Factor and an Index of Tumor Microenvironment Remodeling in Osteosarcoma

Chen, L., Liu, J.-F., Lu, Y., He, X., Zhang, C., & Zhou, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642144 · Cited by 91 · see citing works

Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression

Fan, T. M., Roberts, R. D., & Lizardo, M. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00013 · Cited by 90 · see citing works

Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma

Anand, N., Peh, K. H., & Kolesar, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032858 · Cited by 91 · see citing works

Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy

Luo, Z.-W., Liu, P.-P., Wang, Z.-X., Chen, C.-Y., & Xie, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586580 · Cited by 89 · see citing works

A tumor microenvironment-based prognostic index for osteosarcoma

Wu, C., Gong, S., Duan, Y., Deng, C., Kallendrusch, S., Berninghausen, L. K., Osterhoff, G., & Schopow, N. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00917-3 · Cited by 89 · see citing works

Emerging trends in immunotherapy for pediatric sarcomas

Dyson, K. A., Stover, B. D., Grippin, A., Méndez‐Gómez, H. R., Lagmay, J., Mitchell, D. A., & Sayour, E. J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0756-z · Cited by 88 · see citing works

Recent Insights into Therapy Resistance in Osteosarcoma

Prudowsky, Z. D., & Yustein, J. T. (2020) · Cancers · doi:10.3390/cancers13010083 · Cited by 89 · see citing works

New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?

Danieau, G., Morice, S., Rédiní, F., Verrecchia, F., & Royer, B. B.-L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153751 · Cited by 85 · see citing works

Expression of Lipid-Metabolism Genes Is Correlated With Immune Microenvironment and Predicts Prognosis in Osteosarcoma

Hu, Q., Lei, T., Hu, Y., & Lei, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.673827 · Cited by 84 · see citing works

An overview of resistance to chemotherapy in osteosarcoma and future perspectives

García-Ortega, D. Y., Cabrera-Nieto, S. A., Caro-Sánchez, C. H. S., & Cruz‐Ramos, M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.18 · Cited by 86 · see citing works

Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma

Wang, Y., Yu, W., Zhu, J., Wang, J., Xia, K., Liang, C., & Tao, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1147-6 · Cited by 75 · see citing works

Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies

Ji, Z., Shen, J., Lan, Y., Yi, Q., & Liu, H. (2023) · MedComm · doi:10.1002/mco2.308 · Cited by 68 · see citing works

Long noncoding RNA OIP5-AS1 accelerates CDK14 expression to promote osteosarcoma tumorigenesis via targeting miR-223

Dai, J., Xu, L., Hu, X., Han, G., Jiang, H., Sun, H., Zhu, G., & Tang, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.109 · Cited by 66 · see citing works

The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response

Cascini, C., & Chiodoni, C. (2021) · Cells · doi:10.3390/cells10071668 · Cited by 63 · see citing works

Sarcoma Stem Cell Heterogeneity

Hatina, J., Kripnerová, M., Houfková, K., Pešta, M., Kuncová, J., Šáňa, J., Slabý, O., & Rodrı́guez, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-11096-3_7 · Cited by 58 · see citing works

Bone sarcomas in the immunotherapy era

Heymann, M., Schiavone, K., & Heymann, D. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14999 · Cited by 57 · see citing works

Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation

Liu, C., Wang, M., Xu, C., Li, B., Chen, J., Chen, J., & Wang, Z. (2021) · Journal of Immunology Research · doi:10.1155/2021/8970173 · Cited by 57 · see citing works

Treating osteosarcoma with CAR T cells

Köksal, H., Müller, E., Inderberg, E. M., Bruland, Ø. S., & Wälchli, S. (2018) · Scandinavian Journal of Immunology · doi:10.1111/sji.12741 · Cited by 56 · see citing works

Novel Immunotherapies for Osteosarcoma

Lu, Y., Zhang, J., Chen, Y., Kang, Y., Liao, Z., He, Y., & Zhang, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.830546 · Cited by 56 · see citing works

The Heterogeneity of Osteosarcoma: The Role Played by Cancer Stem Cells

Schiavone, K., Garnier, D., Heymann, M., & Heymann, D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-14366-4_11 · Cited by 54 · see citing works

Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis

Nirala, B. K., Yamamichi, T., Petrescu, D. I., Shafin, T. N., & Yustein, J. T. (2023) · Cancers · doi:10.3390/cancers15205108 · Cited by 51 · see citing works

Regulated macrophage immune microenvironment in 3D printed scaffolds for bone tumor postoperative treatment

Li, C., Li, C., Ma, Z., Chen, H., Ruan, H., Deng, L., Wang, J., & Cui, W. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.04.028 · Cited by 48 · see citing works

Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas

Menéndez, S. T., Gallego, B., Murillo, D., Rodríguez, A., & Rodrı́guez, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122621 · Cited by 48 · see citing works

Transcriptional profiling of canine osteosarcoma identifies prognostic gene expression signatures with translational value for humans

Mannheimer, J., Tawa, G. J., Gerhold, D. L., Braisted, J. C., Sayers, C. M., McEachron, T. A., Meltzer, P. S., Mazcko, C. N., Beck, J. A., & LeBlanc, A. K. (2023) · Communications Biology · doi:10.1038/s42003-023-05208-z · Cited by 47 · see citing works

Exploration of Immune-Related Gene Expression in Osteosarcoma and Association With Outcomes

Liu, W., Xie, X., Qi, Y., & Wu, J. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.19132 · Cited by 46 · see citing works

In vitro three-dimensional cell cultures for bone sarcomas

Muñoz-García, J., Jubelin, C., Loussouarn, A., Goumard, M., Griscom, L., Renodon‐Cornière, A., Heymann, M., & Heymann, D. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100379 · Cited by 45 · see citing works

The Tumor Microenvironment of Pediatric Sarcoma: Mesenchymal Mechanisms Regulating Cell Migration and Metastasis

Ehnman, M., Chaabane, W., Haglund, F., & Tsagkozis, P. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0839-6 · Cited by 43 · see citing works

Exploring the relationship between metabolism and immune microenvironment in osteosarcoma based on metabolic pathways

Wu, C., Tan, J., Shen, H., Deng, C., Kleber, C., Osterhoff, G., & Schopow, N. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-00999-7 · Cited by 47 · see citing works

Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis

Marchais, A., Costa, M. E. M. D., Job, B., Abbas, R., Drubay, D., Piperno‐Neumann, S., Fromigué, O., Gomez‐Brouchet, A., Rédiní, F., Droit, R., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-20-4189 · Cited by 41 · see citing works

A novel risk score model based on eight genes and a nomogram for predicting overall survival of patients with osteosarcoma

Wu, G., & Zhang, M. (2020) · BMC Cancer · doi:10.1186/s12885-020-06741-4 · Cited by 41 · see citing works

Osteosarcoma of the jaws: An overview of the pathophysiological mechanisms

Bertin, H., Gomez‐Brouchet, A., & Rédiní, F. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103126 · Cited by 45 · see citing works

A novel molecular classification method for osteosarcoma based on tumor cell differentiation trajectories

Zhang, H., Wang, T., Gong, H., Jiang, R., Wang, Z., Sun, H., Huang, R., Wang, Y., Wu, Z., Xu, W., et al. (2023) · Bone Research · doi:10.1038/s41413-022-00233-w · Cited by 40 · see citing works

Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer

Green, D., Eyre, H. J., Singh, A., Taylor, J., Chu, J., Jeys, L. M., Sumathi, V. P., Coonar, A. S., Rassl, D. M., Babur, M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1379-0 · Cited by 39 · see citing works

Data-Driven Mathematical Model of Osteosarcoma

Le, T., Su, S., Kirshtein, A., & Shahriyari, L. (2021) · Cancers · doi:10.3390/cancers13102367 · Cited by 39 · see citing works

Tumor-Infiltrating Lymphocytes and Cancer Markers in Osteosarcoma: Influence on Patient Survival

Casanova, J., Almeida, J. S., Reith, J. D., Sousa, L. M., Fonseca, R. L., Freitas-Tavares, P., Santos-Rosa, M., & Rodrigues‐Santos, P. (2021) · Cancers · doi:10.3390/cancers13236075 · Cited by 39 · see citing works

Using the Spleen as anIn VivoSystemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy withα-PD-L1

Markel, J., Noore, J., Emery, E. J., Bobnar, H. J., Kleinerman, E. S., & Lindsey, B. A. (2018) · Sarcoma · doi:10.1155/2018/8694397 · Cited by 37 · see citing works

FENDRR: A pivotal, cancer-related, long non-coding RNA

Zheng, Q., Zhang, Q., Yu, X., He, Y., & Guo, W. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111390 · Cited by 37 · see citing works

Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma

Morales‐Molina, Á., Gambera, S., Leo, A., & Garcı́a-Castro, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001703 · Cited by 37 · see citing works

A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells

Talbot, L. J., Chabot, A., Funk, A., Nguyen, P., Wagner, J., Ross, A. B., Tillman, H. S., Davidoff, A. M., Gottschalk, S. M., & DeRenzo, C. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691741 · Cited by 37 · see citing works

Tumor-associated macrophages in osteosarcoma

Zhao, Y., Zhang, B., Zhang, Q., Ma, X., & Feng, H. (2021) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2100029 · Cited by 37 · see citing works

Osteosarcoma tumor microenvironment: the key for the successful development of biologically relevant 3D in vitro models

Rodrigues, J., Sarmento, B. F. C. C., & Pereira, C. L. (2022) · In vitro models · doi:10.1007/s44164-022-00008-x · Cited by 39 · see citing works

Identification of prognostic biomarkers associated with metastasis and immune infiltration in osteosarcoma

Yang, B., Su, Z., Chen, G., Zeng, Z., Tan, J., Wu, G., Zhu, S., & Lin, L. (2021) · Oncology Letters · doi:10.3892/ol.2021.12441 · Cited by 36 · see citing works

The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis

Tzanakakis, G. N., Giatagana, E.-M., Berdiaki, A., Spyridaki, I., Hida, K., Neagu, M. T., Tsatsakis, A. M., & Nikitovic, D. (2021) · Cancers · doi:10.3390/cancers13102478 · Cited by 37 · see citing works

Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy

Chalopin, A., Gabriel, M. T., Brown, H. K., Vallette, F. M., Heymann, M., Gouin, F., & Heymann, D. (2018) · Journal of bone oncology · doi:10.1016/j.jbo.2018.07.002 · Cited by 35 · see citing works

Identification of potential crucial genes and key pathways in osteosarcoma

Liu, J., Wu, S., Xie, X., Wang, Z., & Lei, Q. (2020) · Hereditas · doi:10.1186/s41065-020-00142-0 · Cited by 35 · see citing works

Immune classification of osteosarcoma

Le, T., Department of Mathematics and Statistics, U. O. M. A., Su, S., & Shahriyari, L. (2021) · Mathematical Biosciences and Engineering · doi:10.3934/mbe.2021098 · Cited by 35 · see citing works

HMGB1 Positive Feedback Loop Between Cancer Cells and Tumor-Associated Macrophages Promotes Osteosarcoma Migration and Invasion

Hou, C., Lu, M., Lei, Z., Dai, S., Chen, W., Du, S., Jin, Q., Zhou, Z., & Li, H. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2022.100054 · Cited by 32 · see citing works

The Role of Macrophages in Sarcoma Tumor Microenvironment and Treatment

Zając, A. E., Czarnecka, A. M., & Rutkowski, P. L. (2023) · Cancers · doi:10.3390/cancers15215294 · Cited by 32 · see citing works

Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma

González-Fernández, Y., Brown, H. K., Patiño‐García, A., Heymann, D., & Blanco‐Prieto, M. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.030 · Cited by 30 · see citing works

Canine models of human cancer: Bridging the gap to improve precision medicine

Nance, R. L., Sajib, A. M., & Smith, B. F. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.12.003 · Cited by 29 · see citing works

T cell exhaustion drives osteosarcoma pathogenesis

Sun, C.-Y., Zhang, Z., Tao, L., Xu, F.-F., Li, H.-Y., Zhang, H.-Y., & Liu, W. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-3928 · Cited by 29 · see citing works

Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies

Liang, H., Cui, M., Tu, J., & Chen, X. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1394339 · Cited by 30 · see citing works

Targeting metastasis in paediatric bone sarcomas

Bull, E. C., Singh, A., Harden, A. M., Soanes, K., Habash, H., Toracchio, L., Carrabotta, M., Schreck, C., Shah, K. M., Riestra, P. V., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02365-z · Cited by 30 · see citing works

Development of a novel immune-related genes prognostic signature for osteosarcoma

Wu, Z., Deng, Y.-J., Zhang, G., Ren, E., Yuan, W., & Xie, Q.-Q. (2020) · Scientific Reports · doi:10.1038/s41598-020-75573-w · Cited by 28 · see citing works

CAR T targets and microenvironmental barriers of osteosarcoma

Zhu, J., Simayi, N., Wan, R., & Huang, W. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2021.12.010 · Cited by 27 · see citing works

Knockdown of CD44 inhibits proliferation, migration and invasion of osteosarcoma cells accompanied by downregulation of cathepsin S

Kong, L., Ji, H., Gan, X., Cao, S., Li, Z., & Yu, J. Z. (2022) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-022-03048-x · Cited by 27 · see citing works

Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma

Cascini, C., Ratti, C., Botti, L., Parma, B., Cancila, V., Salvaggio, A., Meazza, C., Tripodo, C., Colombo, M. P., & Chiodoni, C. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02731-z · Cited by 27 · see citing works

Role of microRNAs in the crosstalk between osteosarcoma cells and the tumour microenvironment

Lei, Y. H., Junxin, C., Huang, Y., Xiaoguang, L., & Yu, B.-S. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100322 · Cited by 25 · see citing works

Development of a Machine Learning-Based Autophagy-Related lncRNA Signature to Improve Prognosis Prediction in Osteosarcoma Patients

Zhang, G., Wu, Z., Li, C., Ren, E., Yuan, W., Deng, Y.-J., & Xie, Q. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.615084 · Cited by 25 · see citing works

Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies

Ying, H., Li, Z., Li, M.-P., & Liu, W. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1217669 · Cited by 26 · see citing works

Bisphosphonates in common pediatric and adult bone sarcomas

Heymann, M., Lézot, F., & Heymann, D. (2020) · Bone · doi:10.1016/j.bone.2020.115523 · Cited by 23 · see citing works

CONUT Score or/and Peripheral Blood CD4+/CD8+ Ratio-Based Web Dynamic Nomograms to Predict the Individualized Survival of Patients with Advanced Osteosarcoma

Yang, Q., Su, Y., Wang, W., Wang, N., Yao, Z., & Zhang, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s251814 · Cited by 24 · see citing works

PLOD2 high expression associates with immune infiltration and facilitates cancer progression in osteosarcoma

Wang, Z., Fan, G., Zhu, H., Yu, L., She, D., Wei, Y., Huang, J., Li, T., Zhan, S., Zhou, S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.980390 · Cited by 25 · see citing works

Ebastine exerts antitumor activity and induces autophagy by activating AMPK/ULK1 signaling in an IPMK-dependent manner in osteosarcoma

Pan, Z., Li, S., Guo, H., Li, Z., Fei, X., Chang, S., Yang, Q., & Cheng, D. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69541 · Cited by 22 · see citing works

Advancing osteosarcoma 3D modeling in vitro for novel tumor microenvironment-targeted therapies development

Costa, S. A., Rodrigues, J., Vieira, C., Dias, S., Viegas, J. S. R., Castro, F., Sarmento, B. F. C. C., & Pereira, C. L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.068 · Cited by 23 · see citing works

Exosomal Long Non-Coding RNA ANCR Mediates Drug Resistance in Osteosarcoma

Hu, X., Wen, Y., Tan, L., Wang, J., Tang, F., Wang, Y., Zheng, C., Zhang, Y., Gong, T., & Min, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.735254 · Cited by 23 · see citing works

Nanozymes for biomedical applications in orthopaedics

Lin, A., Liu, S., & Wei, H. (2022) · Particuology · doi:10.1016/j.partic.2022.08.009 · Cited by 23 · see citing works

Manganese immunotherapy for treating osteosarcoma: Glycosylating 1V209 anchored MnO2 nanosheets prompt pro-inflammatory macrophage polarization

Liang, C., Xiong, N., Liu, M., Chen, Y., Li, W., Xu, J., Sun, Y., Wang, Y., Dong, Y., Fan, W., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101670 · Cited by 23 · see citing works

Histatin‐1 counteracts the cytotoxic and antimigratory effects of zoledronic acid in endothelial and osteoblast‐like cells

Castro, M., Torres, P., Solano, L., Córdova, L. A., & Torres, V. A. (2019) · Journal of Periodontology · doi:10.1002/jper.18-0644 · Cited by 22 · see citing works

Construction of an Immune-Related lncRNA Signature That Predicts Prognosis and Immune Microenvironment in Osteosarcoma Patients

He, Y., Zhou, H., Xu, H., You, H., & Cheng, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.769202 · Cited by 22 · see citing works

Interaction gene set between osteoclasts and regulatory <scp>CD4⁺</scp> T cells can accurately predict the prognosis of patients with osteosarcoma

Li, F., Tang, H., Luo, X., Li, X., Luo, K., Liu, S., Liang, J., Liao, S., Zhong, C., Zhan, X., et al. (2023) · Cancer Science · doi:10.1111/cas.15821 · Cited by 22 · see citing works

Modulating tumor-associated macrophage polarization by anti-maRCO mAb exerts anti-osteosarcoma effects through regulating osteosarcoma cell proliferation, migration and apoptosis

Ding, L., Wu, L., Cao, Y., Wang, H., Li, D., Chen, W., Huang, P., & Jiang, Z. (2024) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-024-04950-2 · Cited by 21 · see citing works

A three-gene signature based on tumour microenvironment predicts overall survival of osteosarcoma in adolescents and young adults

Wen, C., Wang, H., Wang, H., Mo, H., Zhong, W., Tang, J. Y., Lu, Y., Zhou, W., Tan, A., Liu, Y., et al. (2020) · Aging · doi:10.18632/aging.202170 · Cited by 20 · see citing works

Investigating Optimal Chemotherapy Options for Osteosarcoma Patients through a Mathematical Model

Le, T., Su, S., & Shahriyari, L. (2021) · Cells · doi:10.3390/cells10082009 · Cited by 20 · see citing works

Avenues of research in dietary interventions to target tumor metabolism in osteosarcoma

Leite, T. C., Watters, R. J., Weiss, K. R., & Intini, G. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03122-8 · Cited by 20 · see citing works

Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory

Martínez-Vélez, N., Laspidea, V., Zalacain, M., Labiano, S., García-Moure, M., Puigdelloses, M., Marrodan, L., Gonzalez-Huarriz, M., Herrador, G., de la Nava, D., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0565 · Cited by 21 · see citing works

Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma

Jubelin, C., Muñoz-García, J., Cochonneau, D., Moranton, E., Heymann, M., & Heymann, D. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.130 · Cited by 19 · see citing works

Lipopolysaccharide-binding protein expression is associated to the metastatic status of osteosarcoma patients

Heymann, C. J. F., Bobin‐Dubigeon, C., Muñoz-García, J., Cochonneau, D., Ollivier, E., Heymann, M., & Heymann, D. (2022) · Journal of bone oncology · doi:10.1016/j.jbo.2022.100451 · Cited by 19 · see citing works

Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights

Zhang, Y., Jiang, S., Lv, J., Feng, W., Yu, Y., & Zhao, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1584450 · Cited by 22 · see citing works

Ablative and Immunostimulatory Effects of Histotripsy Ablation in a Murine Osteosarcoma Model

Hay, A. N., Imran, K. M., Hendricks-Wenger, A., Gannon, J. M., Sereno, J., Simon, A., López, V. A., Coutermarsh‐Ott, S. L., Vlaisavljevich, E., Allen, I. C., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102737 · Cited by 18 · see citing works

Oxyresveratrol induces apoptosis and inhibits cell viability via inhibition of the STAT3 signaling pathway in Saos‑2 cells

Lv, T., Jian, Z., Li, D., Ao, R., Zhang, X., & Yu, B. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11591 · Cited by 17 · see citing works

Identification of Immune-Related Genes MSR1 and TLR7 in Relation to Macrophage and Type-2 T-Helper Cells in Osteosarcoma Tumor Micro-Environments as Anti-metastasis Signatures

Chen, Z., Huang, H., Wang, Y., Zhan, F., & Quan, Z. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.576298 · Cited by 18 · see citing works

Immune Environment and Osteosarcoma

Heymann, M., & Heymann, D. (2017) · InTech eBooks · doi:10.5772/67448 · Cited by 8 · see citing works

CXCL6-CXCR2 axis-mediated PD-L2+ mast cell accumulation shapes the immunosuppressive microenvironment in osteosarcoma

Wang, C., Lei, Z., Zhang, C., & Hu, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34290 · Cited by 6 · see citing works

The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response

Cascini, C., & Chiodoni, C. (2021) · Cells · doi:10.3390/cells10071668 · Cited by 63 · see citing works

Abstract 4973: The immunosuppressive tumor microenvironment of metastatic osteosarcoma inhibits the cytotoxic effect of tumor-infiltrating lymphocytes

Ligon, J. A., Oke, T. F., Choi, W., Fong, M. H. Y., Levin, A. S., Rhee, D. S., Morris, C. D., Siegel, N. M., Hsieu, E. H., Meyer, C. F., et al. (2019) · Immunology · doi:10.1158/1538-7445.sabcs18-4973

Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications

Zhu, T., Han, J., Liu, Y., Cai, Z., Sun, W. Y., Hua, Y., & Xu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907550 · Cited by 113 · see citing works